Postmarketing surveillance of sumatriptan : patient population, efficacy, and adverse effects
A postmarketing surveillance survey of sumatriptan use comprised 32 questions including patient demographics, headache history, and sumatriptan experience. One hundred and forty-one questionnaires were sent out, and 109 patients responded; a total of 108 patients were included in the data analysis....
Main Author: | |
---|---|
Format: | Others |
Published: |
Scholarly Commons
1994
|
Subjects: | |
Online Access: | https://scholarlycommons.pacific.edu/uop_etds/2273 https://scholarlycommons.pacific.edu/cgi/viewcontent.cgi?article=3272&context=uop_etds |
id |
ndltd-pacific.edu-oai-scholarlycommons.pacific.edu-uop_etds-3272 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-pacific.edu-oai-scholarlycommons.pacific.edu-uop_etds-32722021-09-01T05:17:05Z Postmarketing surveillance of sumatriptan : patient population, efficacy, and adverse effects Wang, Yu-Chin Lily A postmarketing surveillance survey of sumatriptan use comprised 32 questions including patient demographics, headache history, and sumatriptan experience. One hundred and forty-one questionnaires were sent out, and 109 patients responded; a total of 108 patients were included in the data analysis. When compared with the national migraine population, on a percentage basis, significantly more African-Americans, females, young patients (less 45 years of age), and patients with higher mean incomes (>$45,000) were found in the present study of those taking sumatriptan (p Males (N=8) and females (N=55) had a significantly different percentage of relief from the second dose of 94.7%±7.1 and 83.5%±24.4, respectively (p=0.01). An average percent of pain relief from the first dose in those weighing less or greater than 144 pounds was 76.5%±28.3 and 86.9%±16.4, respectively (p=0.023). The incidence of the adverse effects reported in this study was significantly greater than those reported in the literature (p<0.005). 1994-01-01T08:00:00Z text application/pdf https://scholarlycommons.pacific.edu/uop_etds/2273 https://scholarlycommons.pacific.edu/cgi/viewcontent.cgi?article=3272&context=uop_etds University of the Pacific Theses and Dissertations Scholarly Commons Migraine Prevention Headache Prevention Drugs Effectiveness Medicine and Health Sciences Pharmacy and Pharmaceutical Sciences |
collection |
NDLTD |
format |
Others
|
sources |
NDLTD |
topic |
Migraine Prevention Headache Prevention Drugs Effectiveness Medicine and Health Sciences Pharmacy and Pharmaceutical Sciences |
spellingShingle |
Migraine Prevention Headache Prevention Drugs Effectiveness Medicine and Health Sciences Pharmacy and Pharmaceutical Sciences Wang, Yu-Chin Lily Postmarketing surveillance of sumatriptan : patient population, efficacy, and adverse effects |
description |
A postmarketing surveillance survey of sumatriptan use comprised 32 questions including patient demographics, headache history, and sumatriptan experience. One hundred and forty-one questionnaires were sent out, and 109 patients responded; a total of 108 patients were included in the data analysis.
When compared with the national migraine population, on a percentage basis, significantly more African-Americans, females, young patients (less 45 years of age), and patients with higher mean incomes (>$45,000) were found in the present study of those taking sumatriptan (p
Males (N=8) and females (N=55) had a significantly different percentage of relief from the second dose of 94.7%±7.1 and 83.5%±24.4, respectively (p=0.01). An average percent of pain relief from the first dose in those weighing less or greater than 144 pounds was 76.5%±28.3 and 86.9%±16.4, respectively (p=0.023). The incidence of the adverse effects reported in this study was significantly greater than those reported in the literature (p<0.005). |
author |
Wang, Yu-Chin Lily |
author_facet |
Wang, Yu-Chin Lily |
author_sort |
Wang, Yu-Chin Lily |
title |
Postmarketing surveillance of sumatriptan : patient population, efficacy, and adverse effects |
title_short |
Postmarketing surveillance of sumatriptan : patient population, efficacy, and adverse effects |
title_full |
Postmarketing surveillance of sumatriptan : patient population, efficacy, and adverse effects |
title_fullStr |
Postmarketing surveillance of sumatriptan : patient population, efficacy, and adverse effects |
title_full_unstemmed |
Postmarketing surveillance of sumatriptan : patient population, efficacy, and adverse effects |
title_sort |
postmarketing surveillance of sumatriptan : patient population, efficacy, and adverse effects |
publisher |
Scholarly Commons |
publishDate |
1994 |
url |
https://scholarlycommons.pacific.edu/uop_etds/2273 https://scholarlycommons.pacific.edu/cgi/viewcontent.cgi?article=3272&context=uop_etds |
work_keys_str_mv |
AT wangyuchinlily postmarketingsurveillanceofsumatriptanpatientpopulationefficacyandadverseeffects |
_version_ |
1719474034076286976 |